Nathan Hardy
Director of Finance/CFO en SANA BIOTECHNOLOGY, INC. .
Fortuna: 5 M $ al 31/03/2024
Cargos activos de Nathan Hardy
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| SANA BIOTECHNOLOGY, INC. | Director of Finance/CFO | 01/09/2018 | - |
Historial de carrera de Nathan Hardy
Antiguos cargos conocidos de Nathan Hardy.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| JUNO THERAPEUTICS INC | Director of Finance/CFO | 01/08/2017 | 01/06/2018 |
| AMGEN INC. | Director/Board Member | 01/02/2007 | 01/08/2017 |
| Corporate Officer/Principal | 01/02/2007 | 01/08/2017 |
Formación de Nathan Hardy.
| University of Notre Dame | Masters Business Admin |
| University of Utah | Undergraduate Degree |
Estadísticas
Internacional
| Estados Unidos | 6 |
Operativa
| Director of Finance/CFO | 2 |
| Director/Board Member | 1 |
| Corporate Officer/Principal | 1 |
Sectorial
| Health Technology | 4 |
| Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| AMGEN INC. | Health Technology |
| SANA BIOTECHNOLOGY, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
- Bolsa de valores
- Insiders
- Nathan Hardy
- Experiencia
